1. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007; 5:1424–1429. PMID:
17904915.
Article
2. Ng SC, Tang W, Ching JY, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-Pacific Crohn's and colitis epidemiology study. Gastroenterology. 2013; 145:158–165.e2. PMID:
23583432.
Article
3. Zeng Z, Zhu Z, Yang Y, et al. Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China: a prospective population-based study. J Gastroenterol Hepatol. 2013; 28:1148–1153. PMID:
23432198.
Article
4. Yao T, Matsui T, Hiwatashi N. Crohn's disease in Japan: diagnostic criteria and epidemiology. Dis Colon Rectum. 2000; 43(10 Suppl):S85–S93. PMID:
11052483.
5. Penner A, Crohn BB. Perianal fistulae as a complication of regional ileitis. Ann Surg. 1938; 108:867–873. PMID:
17857277.
Article
6. Marzo M, Felice C, Pugliese D, et al. Management of perianal fistulas in Crohn's disease: an up-to-date review. World J Gastroenterol. 2015; 21:1394–1403. PMID:
25663759.
Article
7. Hukkinen M, Pakarinen MP, Piekkala M, Koivusalo A, Rintala R, Kolho KL. Treatment of complex perianal fistulas with seton and infliximab in adolescents with Crohn's disease. J Crohns Colitis. 2014; 8:756–762. PMID:
24447625.
Article
8. Castaño-Milla C, Chaparro M, Saro C, et al. Effectiveness of adalimumab in perianal fistulas in Crohn's disease patients naive to anti-TNF therapy. J Clin Gastroenterol. 2015; 49:34–40. PMID:
25485513.
Article
9. Kawalec P, Mikrut A, Wiśniewska N, Pilc A. Tumor necrosis factor-alpha antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis. Arch Med Sci. 2013; 9:765–779. PMID:
24273556.
10. Su CG, Lichtenstein GR. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. Gastroenterology. 2003; 125:1544–1546. PMID:
14598275.
Article
11. Ueno F, Matsui T, Matsumoto T, et al. Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan. J Gastroenterol. 2013; 48:31–72. PMID:
23090001.
Article
12. Antakia R, Shorthouse AJ, Robinson K, Lobo AJ. Combined modality treatment for complex fistulating perianal Crohn's disease. Colorectal Dis. 2013; 15:210–216. PMID:
22672653.
Article
13. Echarri A, Castro J, Barreiro M, Carpio D, Pereira S, Lorenzo A. Evaluation of adalimumab therapy in multidisciplinary strategy for perianal Crohn's disease patients with infliximab failure. J Crohns Colitis. 2010; 4:654–660. PMID:
21122576.
Article
14. Sands BE, Blank MA, Diamond RH, Barrett JP, Van Deventer SJ. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study. Aliment Pharmacol Ther. 2006; 23:1127–1136. PMID:
16611273.
Article
15. Tozer P, Ng SC, Siddiqui MR, et al. Long-term MRI-guided combined anti-TNF-alpha and thiopurine therapy for Crohn's perianal fistulas. Inflamm Bowel Dis. 2012; 18:1825–1834. PMID:
22223472.
Article